Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAPSE: LAAO + DOAC vs DOAC in AF Patients With Ischemic Stroke
NCT05976685Recruiting
- Sponsor
- Insel Gruppe
- Start
- May 2024
- Primary completion
- Jan 2028
- Countries
- 6
01
Overview
Randomised, open-label trial in Atrial fibrillation (AFib) and ischemic stroke (2 arms), sponsored by Insel Gruppe. Primary endpoint: Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death at 6 months. Started May 2024; status: recruiting.
02
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on NCT05976685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976685.